Post-adolescent acne in women: More common and more clinical considerations

Journal of Drugs in Dermatology

Volumn 11, Issue 6, 2012, Pages 708-713

  Kim, Grace K ^a   Michaels, Brent D ^a  

^a VALLEY HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; COSMETIC; CYPROTERONE; CYPROTERONE ACETATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTROGEN; ESTROSTREP; ETHINYLESTRADIOL PLUS NORETHISTERONE; ETHINYLESTRADIOL PLUS NORGESTIMATE; FLUTAMIDE; GLUCOCORTICOID; ORAL CONTRACEPTIVE AGENT; POTASSIUM SPARING DIURETIC AGENT; PROGESTERONE; SPIRONOLACTONE; UNCLASSIFIED DRUG;

ACNE; ACNE VULGARIS; ADULT DISEASE; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG EFFICACY; ESTROGEN THERAPY; FEMALE; GENETIC PREDISPOSITION; HIRSUTISM; HORMONAL THERAPY; HUMAN; HYPERANDROGENISM; HYPERKALEMIA; HYPERTENSION; LOW DRUG DOSE; MENORRHAGIA; ONSET AGE; ORAL CONTRACEPTION; OVARY POLYCYSTIC DISEASE; POST ADOLESCENT ACNE; PREVALENCE; SEBUM SECRETION; VENOUS THROMBOEMBOLISM;

ACNE VULGARIS; ADOLESCENT; ADULT; AGE FACTORS; ANDROGEN ANTAGONISTS; CONTRACEPTIVES, ORAL, HORMONAL; FEMALE; HUMANS; MENSTRUAL CYCLE; POLYCYSTIC OVARY SYNDROME;

EID: 84863548085     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Goulden V, Stables GI, Cunliffe WJ. The prevalence of facial acne in adults. J Am Acad Dermatol. 1999;41:577-80.
2. Shafer T, Nienhaus A, Vieluf D, et al. Epidemiology of acne in the general population: the risk of smoking. Br J Dermatol. 2001;145:100-104. (Pubitemid 32862794)
3. Goulden V, Clark SM, Cunliffe WJ. Post adolescent acne: a review of clinical features. Br J Dermatol. 1997;136: 66-70. (Pubitemid 27016177)
4. Williams C, Layton AM. Persistent acne in women: implications for the patient and for therapy. Am J Clin Dermatol. 2006;7:281-90. (Pubitemid 46998578)
5. McConnell RC, Fleischer AB Jr, Willford PM, Feldman SR. Most topical tretinoin treatment is for acne vulgaris through the age of 44 years: an analysis of the national ambulatory medical care survey, 1990-1994. J Am Acad Dermatol. 1998;38:221-226. (Pubitemid 28100836)
6. Layton AM, Henderson K, Cunliffe WJ. A clinical assessment of acne scarring. Clin Exp Dermatol. 1994;4:303-308.
7. Layton AM, Seukaran D, Cunliffe WJ. Scarred for life? Dermatol. 1997;195:15-21. (Pubitemid 27366869)
8. Lasek RJ, Chren MM. Acne vulgaris and the quality of life of adult dermatologypatients. Arch Dermatol. 1998;134:454-458. (Pubitemid 28207628)
9. Nelson VL, Qin KN, Rosenfield RL, et al. The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J Clin Endocrinol Metab. 2001;86 (12): 5925-5933. (Pubitemid 33152646)
10. Poli F, Dreno B, Verschoore M. An epidemiological study of acne in female adults: results of a survey conducted in France. J Eur Acad Dermatol Venereol. 2001;15:541-545. (Pubitemid 34041186)
11. Williams C, Layton AM. Persistent acne in women: implications for the patient and for therapy. Am J Clin Dermatol. 2006;7:281-290. (Pubitemid 46998578)
12. Dumont-Wallon G, Dreno B. Specificity of acne in women older than 25 years. Presse Med. 2008;37:585-591.
13. Collier CN, Harper JC, Cantrell WC et al. The prevalence of acne in adults 20 years and older. J Am Acad Dermatol. 2008;58:56-59. (Pubitemid 350298137)
14. Preneau S, Dreno B. Female acne - a different subtype of teenage acne? JEADV. 2011; Aug 16. doi: 10.1111/j.1468-3083.2011.04214.x.
15. Ozdemir S, Ozdemir M, Gorkemli H, et al. Specific dermatologic features of the polycystic ovary syndrome and its association with biochemical markers of the metabolic syndrome and hyperandrogenism. Acta Obstet Gynecol Scand. 2010;89(2):199-204.
16. Williams C, Layton AM. Persistent acne in women: implications for the patient and for therapy. Am J Clin Dermatol. 2006;7(5):281-290. (Pubitemid 46998578)
17. Knaggs HE, Wood EJ, Rizer RL, Mills OH. Post-adolescent acne. Int J Cosmet Sci. 2004;26:129-138. (Pubitemid 38824179)
18. Rivera R, Guerra A. Management of acne in women over 25 years of age. Actas Dermosifiliogr. 2009;100:33-37.
19. 80.10
20. Shaw JC, White LE. Persistent acne in adult women. Arch Dermatol. 2001; 137:1252-1253.
21. Schmitt JV, Masuda PY, Miot HA. Acne in women: clinical patterns in different age-groups. An Bras Dermatol. 2009; 84:349-354.
22. Kligman AM. Post adolescent acne in women. Cutis 1991; 48: 75-7 28.
23. Knaggs HE, Wood EJ, Rizer RL, et al. Post adolescent acne. Int J Cosmet Sci. 2004; 26: 129-38.
24. Capitanio B, Sinagra JL, Ottaviani M et al. Acne and smoking. Dermatoendocrinol. 2009; 1: 129-135.
25. Capitanio B, Sinagra JL, Bordignon V et al. Underestimated clinical features of postadolescent acne. J Am Acad Dermatol. 2010; 63:782-788.
26. Capitanio B, Sinagra JL, Bordignon V, et al. Underestimated clinical features of postadolescent acne. J Am Acad Dermatol. 2010;63:782-788.
27. Deplewski D, Rosenfield RL. Role of hormones in pilosebaceous unit development. Endocr Rev. 2000;21(4):363-392. (Pubitemid 32279645)
28. McLaughlin B, Barrett P, Finch T, et al. Late-onset adrenal hyperplasia in a group of Irish females who presented with hirsutism, irregular menses and/ or cystic acne. Clin Endocrinol. 1990;32:57-64. (Pubitemid 20029945)
29. Azziz R, Sanchez LA, Knochenhauer ES, et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab. 2004;89:453-62. (Pubitemid 38269843)
30. Bunker CB, Newton JA, Kilborn J, et al. Most women with acne have polycystic ovaries. Br J Dermatol. 1989;121(6):675-680. (Pubitemid 20014847)
31. Falsetti L, Gambera A, Andrico S, Sartori E. Acne and hirsutism in polycystic ovary disease: clinical, endocrine- metabolic and ultrasonographic differences. Gynecol Endocrinol. 2002;16:275-284. (Pubitemid 34988913)
32. Chang WY, Knochenhauer ES, Bartolucci AA, Azziz R. Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups. Fertil Steril. 2005;83:1717-1723. (Pubitemid 40824804)
33. Balen A H, Laven JS, Tan SL, et al . Ultrasound assessment of the polycystic ovary: internaltional consensus definitions. Hum Reprod Update. 2003;9:505.
34. Judd HL, Scully RE, Herbst AL, et al. Familial hyper- thecosis: comparison of endocrinologic and histologic findings with polycystic ovarian disease. Am J Obstet Gynecol. 1973;117:976-982.
35. Bulun SE, Adashi EY. The physiology and pathology of the female reproductive system. In: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, editors. Williams textbook of endocrinology. 10th ed. Philadelphia7 Saunders; 2002. 587-664.
36. Borgia F, Cannavo S, Guarneri F, et al. Correlation between endocrinological parameters and acne severity in adult women. Acta Derm Venereol. 2004;84(3):201-204. (Pubitemid 38649397)
37. Thiboutot D, Gilliland K, Light J, et al. Androgen metabolism in sebaceous glands from subjects with and without acne. Arch Dermatol. 1999;135(9):1041-1045. (Pubitemid 29430494)
38. Walton S, Cunliffe WJ, Keczkes K, et al. Clinical, ultrasound and hormonal markers of androgenicity in acne vulgaris. Br J Dermatol. 1995;133(2):249-253.
39. Thiboutot D. Hormones and acne: pathophysiology, clinical evaluation, and thera- pies. Semin Cutan Med Surg. 2001;20:144-153.
40. Lolis MS, Bowe WP, Shalita AR. Acne and systemic disease. Med Clin N Am. 2009;93:1161-1181.
41. Archer JS, Change RJ. Hirsutism and acne in polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2004;18(5):737-754. (Pubitemid 40424608)
42. Azziz R. The evaluation and management of hirsutism. Obstet Gynecol. 2003;5 Pt 1:995-1007. (Pubitemid 36561267)
43. Cassidenti DL, Paulson RJ, Serfaini R, et al. Effects of sex steroids on skin 5 alpha-reductase activity in vitro. Obstet Gynecol. 1991;78(1):103-107.
44. Rabe T, Kowald A, Ortmann J, et al. Inhibition of skin 5 alpha-reductase by oral contraceptive progestins in vitro. Gynecol Endocrinol. 2000;14(4):223-230.
45. Katsambas AD, Dessinioti C. Hormonal therapy for acne: why not as first line therapy? fact and controversies. Clinics in Dermatology. 2010;28(1):17-23.
46. Lowenstein EJ. Diagnosis and management of the dermatologic manifestations of polycystic ovary syndrome. Dermatol Ther. 2006;19(4):210-223. (Pubitemid 44386588)
47. Arowojulu AO, Gallo MF, Lopex LM, et al. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev. 2009;3:CD004425.
48. van Vloten W, van Haselen C, van Zuuren E, Gerlinger C, Heithecker R. The effect of 2 combined oral contraceptives containing either drospiranone or cyproterone acetate on acne and seborrhea. Cutis. 2002:69:2-15.
49. Palep-Singh M, Mook K, Barth J, Balen A. An observa- tional study of Yasmin in the management of women with polycystic ovary syndrome. J Fam Plann Reprod Health Care. 2004;30:163-165. (Pubitemid 38886306)
50. Goulden V, Clark SM, McGeown C, et al. Treatment of acne with intermittent isotretinoin. Br J Dermatol. 1997;137(1):106-108. (Pubitemid 27305920)
51. Kemmeren JM, Tanis BC, vandenBosch MAAJ, Bollen ELEM, Helmerhorst FM, vanderGraaf Y, et al. Risk of arterial throm- bosis in relation to oral contraceptives (RATIO) study: Oral contraceptives and the risk of ischemic stroke. Stroke. 2002;33:1202-1208. (Pubitemid 34517036)
52. Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. Lancet. 1996;348:498-505.
53. Petitti DB. Clinical practice. Combination estrogen-progestin oral contraceptives. N Engl J Med. 2003;349:1443-50. (Pubitemid 37211060)
54. Frangos JE, Alavian CN, Kimball AB, et al. Acne and oral contraceptives: update on women health screening guidelines. J Am Acad Dermatol. 2008;58:781-6.
55. ACOG Committee on Practice Bulletins-Gynecology. ACOG Practice Bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol. 2006;107:1453-1472. 34. ACOG Committee on Practice Bulletins-Gynecology.
56. ACOG practice bulletin. The use of hormonal contraception in women with coexisting medical conditions. Number 18. Int J Gynaecol Obstet. 2001;75:93-106.
57. World Health Organization. Improving access to quality care in family planning: Medical eligibility criteria for contraceptive use. 3rd ed. Geneva, Switzerland: World Health Organization; 2003.
58. Vessey M, Painter R. Oral contraceptive use and cancer. Findings in a large cohort study, 1968-2004. Br J Cancer. 2006;95:385-389. (Pubitemid 44187603)
59. Moreno V, Bosch F, Mun ̃oz N, Meijer C, Shah K, Walboomers J, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: The IARC Multicentric Case-control Study. Lancet. 2002;359:1085-92. (Pubitemid 34270731)
60. Farquhar C, Lee O, Toomath R, et al. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database Syst Rev. 2003;4:CD000194.
61. Cumming DC, Yang JC, Revar RW, et al. Treatment of hirsutism with spironolactone. JAMA. 1982; 247(9):1295-1298. (Pubitemid 12175671)
62. Armanini D, Karbowiaki I, Goi A, et al. In-vivo metabolites of spironolactone and potassium canrenoate: determination of potential anti-androgenic activity by a mouse kidney cytosol receptor assay. Clin Endocrinol. 1985;23(4):341-347. (Pubitemid 16216752)
63. Dorrington-Ward P, McCartney AC, Holland S, et al. The effect of spironolactone on hirsutism and female androgen metabolism. Clin Endocrinol. 1985:23:161-167. (Pubitemid 15015338)
64. Sawaya M. Antiandrogens and androgen inhibitors. In: Se W, ed. Comprehensive dermatologic drug therapy. Philadelphia: W.B. Saunders Co., 2001: 385-401.
65. Shaw JC. Low-dose adjunctive spironolactone in the treatment of acne in women: a retrospective analysis of 85 consecutively treated patients. J Am Acad Dermatol. 2000;43:498-502. (Pubitemid 30666742)
66. Goodfellow A, Alaghband-Zadeh J, Carter G, et al. Oral spironolactone improves acne vulgaris and reduces sebum excretion. Br J Dermatol. 1984;111:209-214. (Pubitemid 14052303)
67. Helfer EL, Miller JL, Rose LI. Side effects of spironolactone therapy in the hirsute woman. J Clin Endocrinol Metab. 1988;66:208-211. (Pubitemid 18027753)
68. Sawaya M. Antiandrogens and androgen inhibitors. In: Se W, ed. Comprehensive dermatologic drug therapy. Philadelphia: W.B. Saunders Co., 2001: 385-401.
69. Derman RJ. Androgen excess in women. Int J Fertil Menopausal Stud. 1996;41(2):172-176. (Pubitemid 26143311)